Clinical trial · Interventional
Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®
IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) in Adults
NCT02453334CI-TRIAL-00051733IRON CLADcompletedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer and Chemotherapy Related Anemia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Injectafer | Drug | — | UNRESOLVED |
| Normal Saline | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Injectafer
- description
- 2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
- interventionNames
- Drug: Injectafer
- type
- PLACEBO_COMPARATOR
- label
- Normal Saline
- description
- Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
- interventionNames
- Other: Normal Saline
Primary outcomes (1)
- measure
- Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects (male of female) ≥ 18 years of age able to give informed consent to the study. * Subjects with non-myeloid malignancies * Receiving chemotherapy as part of their cancer treatment with at least 4 weeks of treatment remaining. * Screening visit central laboratory hemoglobin (Hgb) ≤11 g/dL, but ≥8 g/dL. * Ferritin between 100 and 800 ng/mL and transferrin saturation (TSAT) =\<35% * Subjects must have Eastern Coopertative Oncology Group (ECOG) performance status of 0-2. * Life expectancy of at least 6 months. * Demonstrate the ability to understand the requirements of the study, willingness to abide by study restrictions and to return for the required assessments. Exclusion Criteria: * Previous participation in a ferric carboxymaltose clinical trial. * Known hypersensitivity reaction to any component of ferric carboxymaltose. * Subjects with overt bleeding * Any anemia treatment within 4 weeks before inclusion (oral iron, IV iron, transfusion, or erythropoiesis-stimulating agents). * Subjects on erythropoiesis-stimulating agents. * Requiring dialysis for the treatment of chronic kidney disease. * Any non-viral infection. * Known positive hepatitis with evidence of active disease. * Received an investigational drug within 30 days of screening. * Alcohol or drug abuse within the past 6 months. * Hemochromatosis or other iron storage disorders. * Any other laboratory abnormality, medical condition or psychiatric disorders which in the opinion of the Investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements. * Pregnant or actively trying to become pregnant (Female subjects who are of childbearing age must have a negative pregnancy test at screening and be practicing an acceptable method of birth control during the study).
References
Publications (0)
Data not yet available
No reference posted for this study.